GET DAILY SIGNALSImmunome (IMNM) Q3 2026 Earnings: What to Expect from the Clinical-Stage Biotech
Key Takeaways
- Immunome, Inc. (IMNM) is expected to report its third-quarter 2026 results in early-to-mid November, with consensus estimates pointing to a net loss of roughly $0.61 to $0.64 per share.
- As a clinical-stage oncology company, Immunome generates minimal revenue, so investors will focus on research and development spending, cash runway, and pipeline progress rather than top-line sales.
- In its most recent quarter (Q2 2026), Immunome posted a loss of $0.65 per share, missing the consensus estimate of $0.51 per share by $0.14.
- Key clinical catalysts under watch include the Phase 3 varegacestat program for desmoid tumors and early-stage assets IM-1021 and IM-3050.
- Operating expense trends and the company's cash position will be central themes as management updates its development timeline.
Earnings Context and Why It Matters
Immunome is a clinical-stage biotech focused on first-in-class and best-in-class oncology therapies, including antibody-drug conjugates (ADCs) and radioligand therapies. Because the company has no approved products, its quarterly earnings are less about revenue and more about capital efficiency, clinical execution, and pipeline momentum. I’m watching closely to see whether rising research and development costs are translating into meaningful clinical progress, especially as the lead candidate, varegacestat, advances through a registrational Phase 3 trial. With collaboration revenue from a prior AbbVie agreement having wound down, the update will also clarify how Immunome plans to fund continued development while preserving shareholder value. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts expect Immunome to report a net loss of approximately $0.61 to $0.64 per share for the third quarter of 2026, with consensus revenue estimates in the low hundreds of thousands of dollars, reflecting the company's pre-commercial stage. For context, Immunome reported a loss of $0.65 per share in Q2 2026, missing the consensus estimate of $0.51 per share. Historically, the company has beaten consensus EPS in only three of its last eight quarters, underscoring the difficulty of forecasting expenses for a development-stage biotech. Rather than earnings per share, investors are likely to focus on cash burn, the pace of trial enrollment, and any commentary on upcoming data readouts.
Market Reaction and Investor Sentiment
Sentiment heading into Immunome's third-quarter report is likely to hinge on clinical news flow rather than the financial headline numbers. Development-stage biotech stocks frequently react to pipeline milestones and cash-position updates more than to quarterly losses, and Immunome is no exception. Key risk factors include the potential for disappointing trial data, higher-than-expected research and development spending, and the possibility of future dilutive capital raises. With the company expecting to continue incurring losses for the foreseeable future, investors may remain sensitive to any signals about when additional financing could be needed.
Forward Outlook and Key Factors to Monitor
Following this earnings event, investors should watch the trajectory of the Phase 3 varegacestat program for desmoid tumors, where topline data timing and enrollment progress will be the dominant drivers of sentiment. Any updated guidance on data readouts could meaningfully influence the stock's direction.
Beyond varegacestat, early-stage assets IM-1021 (a ROR1 ADC) and IM-3050 represent additional catalysts. Initial data from IM-1021 and the planned Phase 1 initiation for IM-3050 will help investors gauge the breadth and depth of Immunome's pipeline.
Cost discipline and cash runway also warrant close attention. As clinical activity intensifies, research and development expenses are expected to rise, making the company's liquidity position and any future financing plans an important area of focus. Investors will want to understand how long current cash is sufficient to fund operations and whether future capital raises could dilute existing shareholders.
Finally, industry dynamics in targeted oncology, including competitive developments in ADC and radioligand therapies, may shape how the market interprets Immunome's progress in the quarters ahead.
My Go-To Tool for Earnings Season Research
In my own workflow, Tickeron’s AI Screener helps me quickly filter clinical-stage biotechs by technical patterns, fundamentals, and AI-driven signals. It’s become a reliable way to spot comparable names and monitor volatility around upcoming reports without spending hours on manual screens.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for IMNM turns negative, indicating new downward trend
IMNM saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 77 similar instances where the indicator turned negative. In 70 of the 77 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 58 cases where IMNM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
The 50-day moving average for IMNM moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMNM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
IMNM broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IMNM entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMNM's RSI Indicator exited the oversold zone, 30 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for IMNM just turned positive on October 22, 2026. Looking at past instances where IMNM's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.
Following a +11.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMNM advanced for three days, in 235 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. IMNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.873) is normal, around the industry mean (2.788). P/E Ratio (-7.077) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement